Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded to Sell at BidaskClub

BidaskClub upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong sell rating to a sell rating in a research report released on Saturday, BidAskClub reports.

A number of other brokerages have also recently commented on AUPH. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 16th. HC Wainwright reaffirmed a buy rating and set a $25.00 target price on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $15.65.

AUPH stock traded down $0.07 during midday trading on Friday, reaching $6.26. 290,035 shares of the company’s stock traded hands, compared to its average volume of 327,154. Aurinia Pharmaceuticals has a 52-week low of $5.06 and a 52-week high of $7.85. The company has a market cap of $581.05 million, a PE ratio of -8.24 and a beta of 1.09. The stock’s 50-day moving average is $6.33.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.16). Aurinia Pharmaceuticals had a negative net margin of 8,435.08% and a negative return on equity of 48.36%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts forecast that Aurinia Pharmaceuticals will post -0.65 EPS for the current year.

A number of hedge funds have recently made changes to their positions in AUPH. FMR LLC increased its holdings in Aurinia Pharmaceuticals by 7.9% during the fourth quarter. FMR LLC now owns 5,049,740 shares of the biotechnology company’s stock valued at $34,439,000 after buying an additional 368,781 shares during the last quarter. NEA Management Company LLC increased its stake in shares of Aurinia Pharmaceuticals by 7.6% in the first quarter. NEA Management Company LLC now owns 5,172,683 shares of the biotechnology company’s stock worth $33,622,000 after purchasing an additional 364,200 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth $2,101,000. Deutsche Bank AG increased its stake in shares of Aurinia Pharmaceuticals by 413.2% in the fourth quarter. Deutsche Bank AG now owns 66,200 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 53,300 shares in the last quarter. Finally, Knott David M purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth $343,000. 32.53% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Further Reading: What is a CD ladder?

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.